Humacyte Q2 2024 GAAP EPS $(0.48) Misses $(0.24) Estimate, Cash And Equivalents of $93.6M
Portfolio Pulse from Benzinga Newsdesk
Humacyte (NASDAQ:HUMA) reported a Q2 2024 GAAP EPS of $(0.48), missing the analyst consensus estimate of $(0.24) by 100%. This represents a 118.18% increase in losses compared to the same period last year. The company has cash and equivalents of $93.6M.
August 13, 2024 | 11:02 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Humacyte reported a Q2 2024 GAAP EPS of $(0.48), missing the analyst consensus estimate of $(0.24) by 100%. This significant miss and the 118.18% increase in losses compared to the same period last year are likely to negatively impact the stock price in the short term. The company has cash and equivalents of $93.6M.
The significant miss on earnings per share and the substantial increase in losses compared to the previous year are likely to lead to a negative market reaction. Investors may be concerned about the company's financial health and future profitability, despite the cash reserves of $93.6M.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100